• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

31-year-old millionaire has zero sympathy for unemployed Gen Z's ‘excuses’—he says 'it is scarily easy' to build a business and get rich right now

2

The heiress of $10 billion Perdue Farms and the $12 billion Sheraton Hotels empire wore hand-me-downs, still rides the subway, and flies economy

3

Iran's president admits 'we have many problems' and missiles 'are of no use' as the U.S. chokes its economy while weakening Tehran's grip on Hormuz

1

31-year-old millionaire has zero sympathy for unemployed Gen Z's ‘excuses’—he says 'it is scarily easy' to build a business and get rich right now

2

The heiress of $10 billion Perdue Farms and the $12 billion Sheraton Hotels empire wore hand-me-downs, still rides the subway, and flies economy

3

Iran's president admits 'we have many problems' and missiles 'are of no use' as the U.S. chokes its economy while weakening Tehran's grip on Hormuz
Finance

Fidelity Has Survived Its Unicorn Markdown Crisis

By
Dan Primack
Dan Primack
Down Arrow Button Icon
By
Dan Primack
Dan Primack
Down Arrow Button Icon
January 21, 2016, 2:00 PM ET
102494674
Photograph by Getty Images/Photo Illustration by Kacy Burdette for Fortune
Add Fortune on Google for similar content.

Last fall, we began reporting on how Fidelity Investments published monthly valuation reports that included its private company stock holdings, which include such names as Dropbox, Pinterest, Snapchat and Uber. The existence of such documents seemed to surprise the companies and their other investors, and led many to speculate that startups would no longer allow Fidelity into their new deals. Even portfolio managers at Fidelity were said to be concerned about the backlash.

So much for that.

Health insurance startup Oscar Health is raising a massive new funding round led by Fidelity. Cybersecurity company Malwarebytes today announced a $50 million infusion from the mutual fund giant. Earlier this month, biotech startup Scholar Rock raised $36 million in a financing led by Fidelity. Syros Pharmaceuticals raised $40 million, with Fidelity participating as an existing shareholder. And that’s just over the first few weeks of 2016.

It seems that Fidelity’s cash ― and vote of confidence ― is more important to startups than the vagaries of its fair market valuation committee. Or at least it is for now.

About the Author
By Dan Primack
See full bioRight Arrow Button Icon
Add Fortune on Google for similar content.

Latest in Finance


Most Popular

Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

    Latest in Finance


    Most Popular

    © 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.